# A First-in-Human Single and Multiple Ascending Dose Study of MT-201

> **NCT07219368** · PHASE1 · RECRUITING · sponsor: **Mirador Therapeutics, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** MT-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07219368
- **Lead sponsor:** Mirador Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2026-11-24
- **Final completion:** 2026-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07219368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07219368, "A First-in-Human Single and Multiple Ascending Dose Study of MT-201". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07219368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*